Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635040 | 0.84 | HTR6 (1.00) | HTR6ESR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1635145 | 0.84 | HTR6 (0.77) | HTR6ESR1KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL1633816 | 0.84 | HTR6 (0.77) | HTR6ESR1ALDH1A1 | |
| SCHEMBL1633740 | 0.83 | HTR6 (0.76) | HTR6ESR1LMNAALDH1A1 | |
| SCHEMBL17160204 | 0.78 | ESR1 (0.47) | HTR6ESR1KEAP1NFE2L2SQSTM1 | |
| SCHEMBL1634443 | 0.77 | HTR6 (0.63) | HTR6ESR1KEAP1ALDH1A1HPGD | |
| SCHEMBL1633675 | 0.75 | HTR6 (0.63) | HTR6KEAP1NFE2L2 | |
| SCHEMBL7590717 | 0.74 | KEAP1 (0.62) | KEAP1NFE2L2SQSTM1FFAR4LMNA | |
| SCHEMBL16551868 | 0.71 | PIK3CA (0.55) | KEAP1NFE2L2SQSTM1FFAR4LMNA | |
| SCHEMBL1544054 | 0.70 | LMNA (0.54) | KEAP1NFE2L2SQSTM1FFAR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388189-B2 | Pyrrolotriazinone derivatives as PI3K inhibitors | ALMIRALL, S.A. (ES) | 2016-07-12 | — | — | US | disclosed |
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | US | disclosed |
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291595-A1 | PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3CB, PIK3CD, PIK3CA | HTR6 4175/4885ESR1 4129/4885KEAP1 2563/4885 |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | HTR6 4366/4885ESR1 3635/4885KEAP1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.